<DOC>
	<DOCNO>NCT01565928</DOCNO>
	<brief_summary>The purpose study determine safety MDV3100 give combination Docetaxel men advance prostate cancer .</brief_summary>
	<brief_title>Safety Tolerability Study MDV3100 Combination With Docetaxel Men With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Willing able provide inform consent ; Men , 18 year age old ; Histologically cytologically confirm adenocarcinoma prostate ; Ongoing androgen deprivation therapy Severe concurrent disease ; Known suspect brain metastasis ; History another malignancy within previous 5 year ; Prior treatment docetaxelbased chemotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>docetaxel</keyword>
	<keyword>MDV3100</keyword>
	<keyword>enzalutamide</keyword>
	<keyword>Xtandi</keyword>
</DOC>